Coherus BioSciences ( NASDAQ: CHRS ) is scheduled to announce Q1 earnings results on Thursday, May 9th, after market close. The consensus EPS Estimate is -$0.21 (+72.
0% Y/Y) and the consensus Revenue Estimate is $83.75M (+158.2% Y/Y).
Over the last 2 years, CHRS has beaten EPS estimates 25% of the time and has beaten revenue estimates 13% of the time. Over the last 3 months, EPS estimates have seen 1 upward revision and 2 downward. Revenue estimates have seen 0 upward revisions and 3 downward.
More on Coherus BioSciences Coherus Biosciences: Dumping One Drug But Showing Promise With Another Coherus BioSciences, Inc. (CHRS) Q4 2023 Earnings Call Transcript Coherus gains as oncology focus leads to job cuts Coherus BioSciences Q4 2023 Earnings Preview Seeking Alpha’s Quant Rating on Coherus BioSciences.
